Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in Health Care Workers who received a two-dose BNT162b2-mRNA vaccination. Serological response was evaluated by quantifying anti-RBD and neutralizing antibodies while cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2) produced in response to Spike peptides. BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune response against Spike in all HCW early after the second dose. After 12 weeks from vaccination, the titer of anti-RBD antibodies as well as their neutralization function decreased while the Spike-specific T-cells persisted at the same level as soon after vaccine boost. Of note, a correlation between cellular and humoral response persevered, suggesting the persistence of a coordinated immune response. The long lasting cell-mediated immune response after 3 months from vaccination highlight its importance in the maintaining of specific immunity able to expand again to fight eventual new antigen encountering.

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine / Agrati, Chiara; Castilletti, Concetta; Goletti, Delia; Sacchi, Alessandra; Bordoni, Veronica; Mariotti, Davide; Notari, Stefania; Matusali, G; Meschi, Silvia; Petrone, Linda; Aiello, Alessandra; Najafi Fard, Saeid; Farroni, Chiara; Colavita, Francesca; Lapa, Daniele; Leone, Sara; Agresta, Alessandro; Capobianchi, Maria; Ippolito, Giuseppe; Vaia, Francesco; Puro, Vincenzo. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 12:1(2022). [10.1038/s41598-022-07741-z]

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine

Matusali G;
2022

Abstract

Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in Health Care Workers who received a two-dose BNT162b2-mRNA vaccination. Serological response was evaluated by quantifying anti-RBD and neutralizing antibodies while cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2) produced in response to Spike peptides. BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune response against Spike in all HCW early after the second dose. After 12 weeks from vaccination, the titer of anti-RBD antibodies as well as their neutralization function decreased while the Spike-specific T-cells persisted at the same level as soon after vaccine boost. Of note, a correlation between cellular and humoral response persevered, suggesting the persistence of a coordinated immune response. The long lasting cell-mediated immune response after 3 months from vaccination highlight its importance in the maintaining of specific immunity able to expand again to fight eventual new antigen encountering.
2022
immune response; vaccines; sars-cov-2
01 Pubblicazione su rivista::01a Articolo in rivista
Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine / Agrati, Chiara; Castilletti, Concetta; Goletti, Delia; Sacchi, Alessandra; Bordoni, Veronica; Mariotti, Davide; Notari, Stefania; Matusali, G; Meschi, Silvia; Petrone, Linda; Aiello, Alessandra; Najafi Fard, Saeid; Farroni, Chiara; Colavita, Francesca; Lapa, Daniele; Leone, Sara; Agresta, Alessandro; Capobianchi, Maria; Ippolito, Giuseppe; Vaia, Francesco; Puro, Vincenzo. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 12:1(2022). [10.1038/s41598-022-07741-z]
File allegati a questo prodotto
File Dimensione Formato  
Agrati_Persistent_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.5 MB
Formato Adobe PDF
1.5 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1739757
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 33
social impact